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immune function impacting cross-talk with growth systems
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ABSTRACT
Suppression of growth during infection may aid resource allocation
towards effective immune function. Past work supporting this
hypothesis in salmonid fish revealed an immune-responsive
regulation of the insulin-like growth factor (IGF) system – an endocrine
pathway downstream of growth hormone (GH). Skeletal muscle is
the main target for growth and energetic storage in fish, yet little is
known about how its growth is regulated during an immune response.
We addressed this knowledge gap by characterising muscle immune
responses in size-matched coho salmon (Oncorhynchus kisutch)
achieving different growth rates. We compared a wild-type strain with
twoGH transgenic groups from the samegenetic background achieving
either maximal or suppressed growth – a design separating GH’s direct
effects from its influence on growth rate and nutritional state. Fish were
sampled 30 h post-injection with phosphate-buffered saline (control) or
mimics of bacterial or viral infection. We quantified mRNA expression
levels for genes from theGH,GH receptor, IGF hormone, IGF1 receptor
and IGF-binding protein families, along with immune genes involved
in inflammatory or antiviral responses and muscle growth status
marker genes. We demonstrate dampened immune function in GH
transgenics compared with wild-type. Themuscle of GH transgenics
achieving rapid growth showed no detectable antiviral response,
coupled with evidence of a constitutive inflammatory state. GH and
IGF system gene expression was strongly altered by GH transgenesis
and fast growth, both for baseline expression and responses to
immune stimulation. Thus, GH transgenesis strongly disrupts muscle
immune status and normal GH and IGF system expression responses
to immune stimulation.
KEY WORDS: Growth, Immunity, Growth-immune cross-talk,
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INTRODUCTION
Skeletal muscle is the most important target for growth investment
and energy storage in teleost fish, representing more than half of
body mass in salmonid species. This tissue is remobilised regularly
during life, e.g. upon maturation or during fasting, with the resultant
resources available for allocation to other physiological systems.
The regulation of skeletal muscle mass represents a dynamic
balance between protein synthesis and degradation pathways,
controlled by growth hormone (GH) and insulin-like growth
factors (IGFs) (Johnston et al., 2011; Fuentes et al., 2013). GH is
the master growth regulator in vertebrates, acting on target tissues
via its receptor GHR, or indirectly by stimulating hepatic production
of IGFs (Fuentes et al., 2013). The IGF system comprises IGF-I and
IGF-II hormones, which promote growth through IGF-1R
signalling pathways (Jones and Clemmons, 1995; Wood et al.,
2005), including in skeletal muscle (Johnston et al., 2011). The
action of IGFs is modulated in the extracellular environment by a
family of IGF-binding proteins (IGFBPs) that influence IGF
availability to IGF-1R (Firth and Baxter, 2002; Garcia de la
serrana and Macqueen, 2018). Genes from the GH and IGF
pathways have been expanded by genome duplication events in
teleost evolutionary history (Ocampo Daza et al., 2011; Macqueen
et al., 2013; Lappin et al., 2016; Alzaid et al., 2016a; Robertson
et al., 2017), including a salmonid-specific event that occurred
88–103 mya (Macqueen and Johnston, 2014).
Many past studies of teleosts have investigated the in vivo
regulation of GH and IGF pathway genes under distinct nutritional
states, highlighting a key role for these systems in the growth and
remodelling of skeletal muscle. For example, Atlantic salmon
(Salmo salar L.) fed after a period of fasting showed upregulation of
IGF-I and IGFBP-4, whereas IGF-II, IGF1R and IGFBP-2 were
downregulated (Bower et al., 2008). Reciprocally, muscle IGF-I
transcript levels were downregulated in Atlantic salmon (Breves
et al., 2016), yellowtail (Seriola quinqueradiata) (Fukada et al.,
2012) and tilapia (Oreochromis mossambicus) (Fox et al., 2010)
by fasting, whereas GHR transcripts were induced by fasting in
tilapia (Fox et al., 2010). Despite such progress, to the best of our
knowledge, the regulation of GH and IGF pathway genes during an
immune response in teleost skeletal muscle remains uncharacterised.
It has long been recognised that growth rate and immune function
are highly interrelated in multicellular organisms, and that energetic
allocation into growth must be traded off against immune function
and disease resistance (reviewed in Arendt, 1997). When considering
the underlying molecular mechanisms, past work provides evidence
for cross-talk between the GH and IGF pathways and immune
function (Heemskerk et al., 1999; Yada, 2007; O’Connor et al., 2008;
Smith, 2010; Franz et al., 2016). We recently reported that IGF
signalling is repressed in rainbow trout (Oncorhynchus mykiss) in
response to bacterial and viral infections, with a striking upregulation
of IGFBP subtypes that restrict IGFs from IGF-1R, and potentially
modify immune function (Alzaid et al., 2016a,b). Interestingly,
immune responsive genes from the IGF pathway showed a striking
co-expression with pro-inflammatory cytokine and antiviral genes
regulated by conserved immune signalling pathways (Alzaid et al.,
2016b), supporting the hypothesis that mechanisms have evolved that
limit growth investment as an intrinsic component of host defence.
What little is known about the regulation of GH and IGF pathway
genes in teleost muscle following immune stimulation has come from
in vitrowork. Treatment of Atlantic salmon muscle cell cultures with
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IGFBP-6 subtype, suggested to repress IGF signalling (Pooley et al.,
2013; Heidari et al., 2015). However, in a separate study, treatment of
differentiated Atlantic salmon myotubes with the same cytokine
resulted in limited expression changes in IGF system genes, despite
the verified presence of muscle fibre atrophy (Garcia de la serrana
et al., 2017). Given the dearth of knowledge in this area, an important
goal of the current study was to perform a comprehensive in vivo
analysis of expression responses for GH and IGF pathway genes
following immune stimulation in teleost skeletal muscle.
GH transgenesis offers an ideal model to address mechanisms
of cross-talk between growth and immunity. Salmonid species
overexpressing GH in a wild-type (WT) genetic background show
enhanced appetite, feed intake and food conversion (e.g. Devlin
et al., 2009; White et al., 2016), as well as altered protein, lipid and
carbohydrate metabolism (Raven et al., 2006; Leggatt et al., 2009;
Higgs et al., 2009), with major effects on energy intake and
processing that results in highly elevated growth rate and enhanced
condition factor, including elevated levels of lipid stores (e.g.
Devlin et al., 1994, 2004; Higgs et al., 2009). Rapid growth requires
matched increases in energetic intake, and GH transgenic salmon
will achieve suppressed growth potential (approaching WT) when
provided a WT ration (Rise et al., 2006; Raven et al., 2008). GH
transgenic salmon on a restricted ration have the same plasma IGF-I
levels and liver IGF-I mRNA expression as WT, despite highly
increased plasma GH (Raven et al., 2008), and possess reduced
energy stores relative to WT and fully fed transgenic salmon (Higgs
et al., 2009). This study system can be used to disentangle the
impacts of GH from its influence on feed intake and growth rate. To
date, however, there are no published reports addressing the impact
of GH transgenesis on the response of skeletal muscle to immune
challenge, although it is known that systematic immune function is
reduced in GH transgenic salmon (Jhingan et al., 2003; Kim et al.,
2013).
The aim of the current study was to characterise gene expression
regulation linking growth to immune function within the skeletal
muscle of coho salmon, focusing on the GH and IGF systems.
We contrasted transcriptional responses of genes from both
pathways, in addition to selected markers of immune and muscle
growth status, to immune stimulation in three experimental groups,
comparing WT animals with a GH transgenic strain achieving
either maximal or supressed growth by ration manipulation.
Our findings reveal a disruption to immune function and the
regulation of growth–immune cross-talk in muscle of GH transgenic
animals, with implications for the health of rapidly growing fish
strains used in aquaculture, and for risk assessments concerning
the impacts of transgenic salmon should they be released into
natural environments.
MATERIALS AND METHODS
Experimental design
Experiments on coho salmon, Oncorhynchus kisutch (Walbaum
1792), were performed at Fisheries and Oceans Canada (DFO),
West Vancouver, BC, Canada. This facility is designed to prevent
the escape of transgenic fish to the natural environment. All work
was done in accordance with guidelines of the Canadian Council on
Animal Care, under a permit (#12-017) from the DFO’s Pacific
Regional Animal Care Committee. All studied fish were initially
maintained under common garden conditions (4000 litre tanks
supplied with 10.5±1°C aerated well water, natural photoperiod, at a
density of <5 kg m−3) and fed a commercial diet (Skretting Ltd,
Vancouver, BC, Canada) twice daily at 09:00 h and 15:00 h (3% of
body mass per day). Three experimental groups were generated after
Oakes et al., 2007 and Raven et al., 2008: (i) 19-month-old WT
animals fed to satiation throughout ontogeny (‘WT’); (ii) 6-month-
old GH transgenic animals fed to satiation throughout ontogeny
(transgenic full ration: ‘TF’); and (iii) 17-month-old GH transgenic
animals fed to the WT satiety level throughout ontogeny (transgenic
restricted ration: ‘TR’). Using fish of different ages was necessary to
standardise the confounding effects of body size, owing to different
growth rates among the groups. The WT group was the offspring of
parents collected at the Chehalis River in British Columbia, Canada
(Devlin et al., 2004). The GH transgenic strain (M77) was originally
produced by microinjecting the GH gene construct of sockeye
salmon (Oncorhynchus nerka; OnMTGH1) into the eggs of WT
parents from the same WT strain (Devlin et al., 1994, 2004), and
subsequently maintained by crossing transgenic males with Chehalis
River females at each generation to maintain a wild-type genetic
background.
For each experimental group, 60 animals [size-matched, immature
and of unknown sex; mean mass±s.d. as follows: WT: 74.2±3.6 g,
TF: 77.9±6.1 g, TR: 78.6±3.3 g; mean condition factor (K):
calculated as K=(M×l3)×100, where M is mass (g) and l is length
(mm), as follows:WT: 1.15, TF: 1.17; TR: 1.12] were marked by fin-
clips and allocated into four separate 70 litre tanks prior to immune
stimulation. The fish were then intraperitoneally injected with either:
(i) polyinosinic–polycytidylic acid (Poly I:C) at 200 µg per 100 g fish
mass (24 fish per tank per group); (ii) peptidoglycan (PGN) at 200 µg
per 100 g fish mass (24 fish per tank per group); or (iii) phosphate-
buffered saline (PBS) (i.e. control, 24 fish per tank per group). After
treatment, fish were re-stocked into the 4000 litre tanks and
maintained under the common garden design described above, with
the exception that feed was not provided. The concentrations of Poly
I:C and PGN usedwere based on past studies (Kono and Sakai, 2001;
Jensen et al., 2002; Lockhart et al., 2004; Kono et al., 2004).
At the point of sampling, fish were killed by a lethal dose of
tricaine methanesulphonate (200 mg l−1; Syndel Laboratories Ltd,
Vancouver, BC, Canada; buffered in 400 mg l−1 sodium bicarbonate)
after prior sedation using Aquacalm (1 mg l−1; Syndel Laboratories).
For each group, 10 fish were randomly sampled 30 h post-treatment.
A panel of tissues, namely skeletal muscle, intestine, liver, head
kidney and spleen, were rapidly team sampled. For all tissues except
skeletal muscle, samples were fixed in RNAlater™ (ThermoFisher
Scientific) overnight at 4°C and stored at −80°C. For skeletal muscle,
the samples were split, with half fixed in RNAlater™ as described
above and the other half flash frozen on dry ice. For the current study,
the skeletal muscle samples were shipped on dry ice to the School of
Biological Sciences, University of Aberdeen, UK, where samples
were stored at −70°C until analysis. Samples fixed in RNAlater™
were used for all molecular analyses described below (N=5 fish
per group per treatment; 45 samples).
Primer design
Details of primer pairs for 47 quantitative PCR (qPCR) assays
performed in the study are provided in Table S1, including citations to
previously published primers. Coho salmon genes of interest were
initially acquired using Atlantic salmon and rainbow trout orthologues
acquired from the NCBI database as queries in BLASTn searches
against two published coho salmon transcriptomes (Kim et al., 2016;
Garcia de la serrana et al., 2015) and a sequence capture data set that
included target genes from the GH and IGF systems for coho salmon
(Lappin et al., 2016; Robertson et al., 2017). When the current paper
was in preparation, a high-quality genome was released for coho
salmon (NCBI accession; GCA_002021735.1). Hence, a larger pool
of gene models became available, which were used to check all coho
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salmon sequences targeted by qPCR; where possible, we report
coho-specific accession numbers for all gene targets (Table S1).
For most IGF system genes, we found that published primers from
Atlantic salmon (Macqueen et al., 2013) and rainbow trout (Alzaid
et al., 2016a,b) were conserved in coho salmon. New primer
pairs were designed for IGFBP-1A2 and IGFBP-5B1 owing to
significant mismatches between published primers and coho
salmon. Salmonid-specific genes encoding GH are known for
salmonids (previously named GH1 and GH2) (e.g. McKay et al.,
2004; Robertson et al., 2017) and both were identified in coho
salmon (accession numbers in Table S1). We initially tested
primers conserved across both GH duplicates and detected limited
muscle transcript expression: because this primer pair binds both
genes equally, we concluded that neither GH duplicate was
sufficiently expressed to warrant design of additional primers.
A past study identified salmonid-specific duplicates of GHR
(GHR1 and GHR2), including in coho salmon (Very et al., 2005), for
which we designed new primer pairs that bind divergent regions
among the duplicates (Table S1). Additional primers were used
for marker genes known to be strongly upregulated by immune
stimulation or to be directly involved in muscle growth and
development (described in Castro et al., 2015; Alzaid et al., 2016a,b).
Quantitative gene expression analyses
Total RNA extraction and reverse transcription was performed as
described previously (Alzaid et al., 2016b). RNAwas extracted using
TRIzol Reagent (Sigma-Aldrich), following the manufacturer’s
instructions. RNA quantity and purity were measured using
A260/280 and A260/230 NanoDrop™ UV spectrophotometry
(ND-1000, Thermo Scientific™) and RNA integrity confirmed by
agarose gel electrophoresis. Reverse transcription was done using a
QuantiTect Reverse Transcription Kit (Qiagen), including a step to
remove genomic DNA. Transcript levels of the target genes were
measured with qPCR using an Mx3005P qPCR System with
Brilliant III Ultra-Fast SYBR Green (Agilent Technologies). The
efficiency of qPCR assays was calculated using LinRegPCR
(Ruijter et al., 2009). Data analyses were performed in GenEx
(MultiD Analyses AB) using the variance-based algorithm
NormFinder (Andersen et al., 2004) to test the suitability of five
potential reference genes (RpL4, RpS13, RpS29, ACTB and EF1A)
for data normalisation; this approach identified RpL13 and ACTB
as the most stable pair of reference genes across all samples
(combined s.d.: 0.14). The same genes were the most stably
expressed considering variation in expression across treatments
(combined s.d.: 0.10) and fish groups (combined s.d.: 0.10), and
were used to normalise the expression data for each experimental
gene. Within GenEx, efficiency-corrected, normalised arbitrary
transcript levels were placed on a relative scale that was quantitatively
comparable across different genes.
Statistics
Statistical analyses were performed in Minitab v.18 (Minitab Inc.).
Differences in baseline gene transcript levels among fish groups for
the control animals (PBS injected) were identified using one-way
ANOVA, with Tukey’s post hoc test to reveal significant pair-wise
differences among groups (i.e. WT–PBS versus TR–PBS versus
TF–PBS). The effect of PGN and Poly I:C on gene expression was
tested (separately for each immune mimic) using two-way ANOVA,
including the effect of treatment, fish group and treatment × group
interaction. When two-way ANOVA revealed a significant effect of
treatment or a significant treatment × group interaction, we used
Tukey’s post hoc test to: (i) identify significant pair-wise differences
within each fish group due to treatment (i.e. WT–control versus
WT–PGN or WT–Poly I:C; TR–control versus TR–PGN or
TR–Poly I:C; TF–control versus TF–PGN or TF–Poly I:C); and
(ii) identify significant pair-wise differences in transcript
levels among fish groups subjected to each immune treatment
(i.e. WT–PGN versus TR–PGN versus TF–PGN; WT–Poly I:C
versus TR–Poly I:C versus TF–Poly I:C). For all parametric
analyses, we tested whether the fitted model residuals conformed
to assumptions of normality (Anderson–Darling test) and
homoscedasticity (Levene’s test). Box–Cox transformations and,
if necessary, a non-parametric test (Kruskal–Wallis) were employed
when data failed to meet these assumptions.
RESULTS
GH transgenesis alters baseline expression of GH and IGF
system genes in skeletal muscle
We first assayed the baseline mRNA levels of all tested GH and IGF
pathway genes in the muscle of unstimulated control fish for the
three experimental groups (Fig. 1; Table 1). For the mRNAs
encoding hormones, GH was expressed at low levels in all groups,
IGF-I expression was not different across the groups, whereas
IGF-II expression was significantly elevated (by ∼2.3-fold) in TR
versus WT (Fig. 1A; Table 1). IGF-II levels were substantially
(∼20-fold) higher than IGF-I in all groups (Table 1). Among the
assayed receptors, GHR1 transcript levels were significantly lower
in TF versus WT and TF versus TR comparisons (by ∼4.5- and
2.5-fold, respectively), whereasGHR2 expressionwas not significantly
different across groups (Fig. 1B; Table 1). Expression of IGF1R-a2
was higher than other IGF1R family genes (i.e. IGF1R-a1 and
IGF1R-b) in all groups, and significantly higher in TF versus WT,
by ∼2.4-fold (Fig. 1C; Table 1). The expression of four out of
11 IGFBP family member genes differed significantly between the
three groups (Table 1). No muscle expression was detected for
IGFBP-1B1, -1B2, -2B1, -2B2, -3B1, -3B2, -6A1 and -6A2. IGFBP-
1A2 transcript levels were significantly higher (by ∼3.8-fold) in TF
versus WT but were not significantly different comparing TF and
TR (Fig. 1D). Conversely, IGFBP-3A1, IGFBP-5B1 and IGFBP-
6B2 were each most highly expressed in the TR group and always
significantly higher than WT (and significantly higher than TF for
IGFBP-5B1 only) (Fig. 1E–G; Table 1). For the tested markers of
muscle growth status, most were not differentially expressed
across groups, including FBXO32 (Tacchi et al., 2010), which
encodes an E3-ubiquitin ligase involved in structural protein
turnover, TNNI2 and MYL1, which encode sarcomere proteins, and
myoG, which is a transcription factor for myogenic differentiation
(Table 1). However, transcript levels of MyoD1a (Macqueen and
Johnston, 2006), a transcription factor for myogenic determination
and differentiation, were significantly elevated in TF versus WT
(Fig. 1H; Table 1).
GH transgenesis alters skeletal muscle immune
gene expression
To assess skeletal muscle responses to PGN, we measured transcript
levels for markers of pro-inflammatory cytokines (TNF-α, IL-1β
and IL-8) and acute-phase proteins (SAA and HAMP) (Fig. 2A;
Table S2) after Castro et al., 2015. A response to PGN was detected
in each group, evidenced by a significant induction of all tested
marker genes barring TNF-α in TF (Fig. 2A; Table S2). The lack
of TNF-α response in TF was coupled with a respective 5.4- and
4.1-fold higher baseline expression versus WT and TR (Fig. 2A;
Table S2). In addition, the magnitude of observed responses of
TNF-α, IL-1β and IL-8 was distinct among the fish groups; being
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highest in WT, intermediate in TR and lowest or non-existent in TF,
leading to a significant treatment × group interaction (Fig. 2A;
Table S2). In contrast, SAA and HAMP showed a highly significant
induction in all groups, without any treatment × group interaction
(Fig. 2A; Table S2).
To assess skeletal muscle responses to Poly I:C, we measured
transcript levels for markers of cytokines and proteins involved in the
antiviral response (IFN-a, γ-IP, Mx, LMP2 and RSAD2) (Fig. 2B;
Table S2) after Castro et al., 2015. Each tested marker was
significantly induced in WT and TR but not TF (Fig. 2B;
Table S2). The responses of these genes showed a striking
and consistent difference among groups, with between ∼17- and
470-fold induction across the five genes in WT, compared with
between ∼1.6- and 34-fold in TR and no upregulation in TF,
leading to a highly significant treatment × group interaction
(Fig. 2B; Table S2).
GH transgenesis alters GH and IGF system expression
responses to immune stimulation
PGN altered the expression of several GH and IGF pathway genes,
evidenced by significant overall treatment effects, and/or significant
treatment × group interaction effects, reflecting different responses
among fish groups (Table 2). PGN had no effect on the expression
of mRNAs encoding GH or IGF-I but IGF-II was significantly
upregulated inWT and downregulated in TR (Table 2). PGN altered
the expression of mRNAs encoding all tested receptors, with
some genes showing a significant treatment effect (GHR1,GHR2
and IGF1R-b) and these and others showing a significant
treatment × group interaction (GHR1, IGF1R-a1 and -a2) (Table 2).
GHR1was significantly downregulated in WT, unchanged in TR and
upregulated in TF by >5-fold, whereas IGF1R-a2 showed a reciprocal
pattern of induction inWTand downregulation in TF (Table 2). Seven
genes encoding IGFBPs showed a significant treatment × group
interaction and were typically upregulated in WT (significant effect
for IGFBP-1A1 and -6B1) and downregulated in GH transgenic
fish (significant effect for IGFBP-3A2 and -6B2 in TR, and for
IGFBP-1A2, -2A and -3A2 in TF) (Table 2). For several IGFBP
genes, the response to PGN in WT led to transcript levels that
were significantly higher than observed in GH transgenic fish,
including IGFBP-1A1 (WT>TR and TF), IGFBP-2A (WT>TF)
and IGFBP-6B1 (WT>TR) (Table 2). Considering the marker
genes for muscle growth status, we observed no significant responses
to PGN for genes encoding sarcomeric proteins (Table 2). Whereas
myoG showed a significant treatment × group interaction, there were
no significant differences in expression among the three groups
(Table 2). MyoD1a showed a significant downregulation in TF
compared with WT (Table 2).
Poly I:C altered the expression of several GH and IGF pathway
genes, which typically showed distinct responses between WT
and GH transgenic animals (Table 3). Among the tested hormones,
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Fig. 1. Growth hormone (GH) and insulin-like growth factor (IGF) pathway genes with altered baseline expression comparing wild-type and GH
transgenic fish. Box plots are shown for genes where a significant effect (P<0.05) was observed by one-way ANOVA comparing the three tested fish
groups (N=5 fish per group). Black circles within box plots show mean transcript levels. Different letters indicate significant differences among fish groups
(Tukey’s post hoc analysis). Full data (including means±s.d.) are given in Table 1.
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IGF-II showed a significant downregulation in both transgenic
groups (Table 3). For the tested receptors, GHR1 was significantly
induced in TF, whereas IGF1R-a2 was significantly induced in
WT but significantly downregulated in TF, and IGF1R-b showed
significant downregulation in both GH transgenic groups (Table 3).
The expression of seven genes encoding IGFBPs was affected
by Poly I:C, with IGFBP-1A2 showing significant upregulation in
WT and significant downregulation in both GH transgenic groups,
leading to WT having significantly greater transcript levels
(Table 3). IGFBP-1A1 mRNA was significantly downregulated in
TF specifically and was significantly more abundant in WT than TF
following Poly I:C treatment (Table 3). IGFBP-2A, IGFBP-5B2,
IGFBP-6B1 and IGFBP-6B2 were significantly downregulated in
both GH transgenic groups (Table 3). Considering the markers of
muscle growth status, a significant treatment × group interaction
was observed for TNNI2, with the TF transcript level post-treatment
significantly higher than WT (Table 3). MyoD1a was significantly
downregulated by Poly I:C in TF (Table 3).
Table 1. Differences in baseline expression of growth hormone (GH) and insulin-like growth factor (IGF) system genes comparing wild-type with
transgenic coho salmon
Gene P-value WT transcript level TR transcript level TF transcript level
Hormones
GH 0.77 0.01±0.01 0.01±0.00 0.01±0.01
IGF-I 0.33 0.01±0.01 0.02±0.01 0.02±0.01
IGF-II 0.01 0.18±0.06a 0.42±0.15b 0.34±0.06a,b
Receptors
GHR1* 0.001 1.43±0.90a 0.86±0.24a 0.32±0.13b
GHR2 0.24 0.73±0.67 0.56±0.13 0.43±0.09
IGF1R-a1 0.40 0.07±0.03 0.08±0.02 0.09±0.02
IGF1R-a2 0.001 0.31±0.07a 0.44±0.12a 0.74±0.21b
IGF1R-b 0.36 0.07±0.02 0.10±0.03 0.09±0.04
IGF-binding proteins
IGFBP-1A1 0.49 0.13±0.08 0.13±0.05 0.18±0.08
IGFBP-1A2 0.01 0.13±0.09a 0.28±0.04a,b 0.50±0.23b
IGFBP-2A* 0.09 0.22±0.09 0.41±0.10 0.83±1.08
IGFBP-3A1 0.02 0.06±0.03a 0.13±0.02b 0.09±0.04a,b
IGFBP-3A2 0.06 0.20±0.07 0.43±0.20 0.42±0.16
IGFBP-4* 0.69 1.03±1.30 0.91±0.42 0.65±0.14
IGFBP-5A 0.10 0.02±0.02 0.03±0.03 0.01±0.01
IGFBP-5B1* 0.01 0.66±0.23a 1.87±1.01b 0.80±0.22a
IGFBP-5B2 0.18 0.75±0.57 1.23±0.19 0.97±0.27
IGFBP-6B1 0.07 0.17±0.06 0.42±0.22 0.27±0.14
IGFBP-6B2 0.01 0.86±0.47a 2.42±0.83b 1.93±0.69a,b
Muscle growth status markers
FBXO32 0.47 13.70±15.80 5.10±0.94 9.90±9.99
TNNI2 0.52 487.72±369.77 337.85±181.83 324.16±90.35
MYL1 0.89 230.07±136.61 198.63±75.88 221.97±92.12
myoG 0.16 0.58±0.39 0.95±0.16 0.69±0.28
MyoD1a 0.04 2.83±1.21a 3.66±0.97a,b 4.88±1.22b
Data shown are for control (phosphate-buffered saline-injected) fish and represent relative transcript levels (means±s.d., N=5) shown as arbitrary units
normalised to two empirically validated reference genes (RpL13 and ACTB). The data are quantitatively comparable across genes and among fish groups.
Probability values are from one-way ANOVA testing for an effect of fish group. Different superscript letters highlight significant differences in transcript levels
among groups according to Tukey’s post hoc test. The symbol ‘*’ shows genes where the data required Box–Cox transformation.
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Fold-change Fold-change Fold-change Fold-change Fold-change Fold-change
13.14*
9.20*
18.53*
19.23*
PBS PGN PBS
WT TR TF WT TR TF
PGN PBS PBS Poly I:C PBS Poly I:C PBS Poly I:CPGN
3.72*
10.26*
7.79*
24.40*
48.92*
0.58 IFN-a
Mx
LMP2
RSAD2
γ-IP3.87*
145.05*
25.06*
80.12*
16.94*
468.70*
4.93*
5.76*
0.68
0.45
0.92
0.39
6.27
6.27*
1.63*
33.94*
4.44*
17.56*
43.56*
Fig. 2. Impact of immune stimulation on the expression of host defence genes comparing wild-type and growth (GH) transgenic fish. (A) Peptidoglycan
(PGN) treatment. (B) Polyinosinic–polycytidylic acid (Poly I:C) treatment. Transcript expression is presented as bubble plots of sizes comparable among
fish groups for each shown gene. The bubble area is proportional to mean transcript levels (N=5 fish per group). Two-way ANOVA revealed that all the
shown genes were significantly induced (P<0.05) by the immune stimulations (Table S2) and Tukey’s post hoc test identified significant changes in gene
expression between control and treated fish, shown by asterisks next to accompanying fold-change values (calculated by dividing mean treatment by mean
control, N=5 per mean). Full data (means±s.d.) are given in Table S2. PBS, phosphate-buffered saline.
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DISCUSSION
Animals have evolved defence mechanisms to eradicate pathogens
via pathways that are energetically costly (e.g. Bonneaud et al.,
2003; Lochmiller and Deerenberg, 2000). Recent studies in fish
have revealed that the expression of genes from the IGF system is
altered during immune responses to bacterial and viral infections,
consistent with growth downregulation, theoretically allowing
energetic resources to be invested in immune function (Pooley
et al., 2013; Alzaid et al., 2016a,b). Until the current study, little
attention had been given to the regulation of growth following
immune stimulation in fish skeletal muscle, which is the most
important tissue for growth investment. In addition to demonstrating
baseline differences in GH and IGF system gene expression between
wild-type and GH transgenic coho salmon, we demonstrate that
muscle immune status is disrupted by GH transgenesis as well as the
impacts of GH on growth and physiological status. This observation
was coupled to striking differences in GH and IGF system regulation
post-immune stimulation, suggesting ‘normal’ cross-talk between
muscle growth and immune function is disrupted byGH transgenesis.
As differences in GH and IGF system expression caused by GH
transgenesis in coho salmon have been reported elsewhere (e.g.
Raven et al., 2008; Devlin et al., 2009), we focus discussion around
novel links between growth and immune function.
GH transgenesis disrupts immune status of skeletal muscle
In response to PGN, the cytokines IL-1β, IL-8 and TNF-α were
strongly induced in WT, confirming an inflammatory response.
Whereas TR and TF groups showed a comparable response, the
magnitude of cytokine induction was lower, and particularly
attenuated in TF, which failed to upregulate TNF-α. These findings
suggest that the GH transgenic fish have a reduced inflammatory
response, particularly when maximal growth rate is being achieved
under satiation feeding. Another potential explanation is that the
inflammatory response has distinct temporal dynamics in GH
transgenic and WT fish, which were not captured in our study
(30 h post-treatment). However, genes encoding the acute-phase
proteins Serum amyloid A and Hepcidin were induced at comparable
levels in all fish groups, indicating that GH transgenesis does not
compromise all effectors of innate immunity in muscle, quantitatively
or in terms of temporal dynamics. Altered expression of pro-
inflammatory cytokines in GH transgenics indicates disruption in
cross-talk between skeletal muscle and immune function (reviewed in
Pillon et al., 2013). This could relate to differences in the number
of immune cells residing within muscle, e.g. macrophages and
granulocytes, given past reports that GH transgenic salmon develop
fewer white cells than wild-type fish (Kim et al., 2013). Constitutive
upregulation of TNF-α in the TF group suggests that growth rate and/
or nutritional status modulate the impact of GH on TNF-α regulation
and could imply a permanent inflammatory state that classically
would be deemed pathological (Pillon et al., 2013). TNF-α, along
with other pro-inflammatory cytokines including IL-1 family
members, also positively regulate muscle development (e.g. Chen
et al., 2007; Costamagna et al., 2015). Hence, disrupted cytokine
expression has implications for myogenesis in addition to health
Table 2. Effects of peptidoglycan (PGN) on expression of growth hormone (GH) and insulin-like growth factor (IGF) system genes comparing
wild-type with transgenic coho salmon groups
Gene P-value treatment
P-value treatment ×
group interaction
WT fold-change;
transcript level
TR fold-change;
transcript level
TR fold-change;
transcript level
Hormones
GH 0.66 0.71
IGF-I 0.67 0.29
IGF-II 0.18 <0.0001 2.11*; 0.38±0.04a 0.54*; 0.23±0.03a,b 0.62; 0.21±0.08b
Receptors
GHR1‡ 0.02 <0.0001 0.33*; 0.47±0.21a 1.80; 1.55±0.46b 5.05*; 1.64±0.58b
GHR2 0.02 –
IGF1R-a1 0.19 0.002 1.48; 0.09±0.02a 0.66; 0.05±0.02b 0.58; 0.05±0.02b
IGF1R-a2 0.88 <0.0001 2.70*; 0.84±0.16a 1.13; 0.35±0.11b 0.37*; 0.27±0.05b
IGF1R-b 0.03 0.09
IGF-binding proteins
IGFBP-1A1 0.97 <0.0001 2.25*; 0.30±0.09a 0.50; 0.07±0.02b 0.47; 0.09±0.05b
IGFBP-1A2 0.01 <0.0001 2.15; 0.29±0.11a 0.46; 0.13±0.05a 0.32*; 0.16±0.05a
IGFBP-2A‡ 0.22 0.001 1.86; 0.40±0.13a 0.68; 0.28±0.07a,b 0.23*; 0.19±0.03b
IGFBP-3A1 0.27 0.78
IGFBP-3A2 0.01 0.001 1.77; 0.35±0.13a 0.33*; 0.14±0.02a 0.39*; 0.17±0.09a
IGFBP-4 0.05 –
IGFBP-5A 0.57 0.02 0.89; 0.02±0.01a 0.19; 0.01±0.01a 3.96; 0.03±0.02a
IGFBP-5B1‡ 0.90 0.09
IGFBP-5B2 0.58 0.47
IGFBP-6B1 0.87 0.001 2.81*; 0.48±0.24a 0.32; 0.13±0.07b 0.80; 0.22±0.11a,b
IGFBP-6B2 0.05 0.002 1.89; 1.62±0.35a 0.51*; 1.24±0.52a 0.57; 1.10±0.38a
Muscle growth status markers
FBXO32 0.02 0.23
TNNI2 0.17 0.06
MYL1 0.11 –
myoG 0.98 0.04 1.55; 0.90±0.14a 0.75; 0.71±0.13a 0.88; 0.61±0.17a
MyoD1a 0.002 <0.0001 1.19; 3.38±0.87a 0.82; 3.00±0.65a,b 0.30*; 1.46±0.33b
Fold-change values (underlined: calculated by dividing the mean PGN treatment by the mean control transcript levels, N=5 fish per mean) are given for
genes where a significant treatment × group interaction was recorded by two-way ANOVA (the symbol ‘*’ indicates a significant expression change according
to Tukey’s post hoc test). For the same genes, relative transcript levels are shown post-PGN treatment (means±s.d., N=5) and represent arbitrary units
normalised to two empirically validated reference genes (RpL13 and ACTB) that are quantitatively comparable across genes and among fish groups (different
superscript letters highlight significant differences among groups according to Tukey’s post hoc test). The symbol ‘‡’ shows genes where the data required
Box–Cox transformation. The symbol ‘–’ shows genes where a Kruskal–Wallis test was done testing for a treatment effect only.
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status. GH transgenic coho salmon were previously shown to have
higher susceptibility to the bacterium Aeromonas salmonicida (Kim
et al., 2013). These data imply systematic attenuation of innate
immunity, but more data will be needed to confirm this finding in
primary immune tissues, as the immune gene expression data
presented here was restricted to skeletal muscle.
In response to Poly I:C, antiviral gene markers showed robust
expression induction in skeletal muscle of WT fish. However, the
same genes showed a lower magnitude of induction in TR and
were not induced in the TF group. These antiviral genes are effectors
of Type-I interferon signalling (e.g. Martin et al., 2007), which
controls viral replication by inhibiting host translation and protein
synthesis (Haller et al., 2007; Sadler and Williams, 2008). Our
results may be explained by the presence of ubiquitous signalling
towards new protein synthesis in the TF group through the IGF–
PI3K–Akt–mTOR pathway downstream of GH (Egerman and Glass,
2014). Past studies have provided evidence for cross-talk between
interferon signalling and this pathway (e.g. Kaur et al., 2008),
providing possible mechanisms by which an antiviral response is
attenuated in favour of protein synthesis. However, as markers for
Type-I interferon signalling showed attenuated expression in the TR
group, which have wild-type growth rate and IGF-I levels (Raven
et al., 2008), our findings imply a direct role for GH in limiting
expression of these antiviral genes. Future work should establish
whether the absence of antiviral gene induction in GH transgenic
salmon muscle is a consequence of systematic attenuation in antiviral
immunity or linked to this tissue’s key role as a target for growth.
While our findings are also compatible with an altered timing of the
antiviral response, the striking observed difference between WT and
GH transgenic fish, and indeed between TR and TF, is difficult to
rationalise solely due to distinct temporal dynamics.
GH transgenesis alters GH and IGF system expression
responses to immune stimulation
The attenuation in immune gene expression in GH transgenics was
coupled to complex changes in expression of GH and IGF system
genes upon immune stimulation. As the same wild-type genetic
background was maintained in all fish studied (i.e. differing
genetically only by the presence of a GH transgene), the WT group
provides a control for the gene expression responses of GH
transgenics to immune stimulation. The hypothesis that effective
immune function is aided by re-allocation of resources during
infection (‘growth-immune trade-off hypothesis’) predicts that
the WT group, which has presumably evolved under selection to
balance growth and immune investment, should restrict growth
by either inhibiting pro-growth gene expression or upregulating
growth-inhibiting genes. Reciprocally, GH transgenic fish, particularly
the TF group, where rapid growth rate is being realised, should have
reduced scope for the same molecular responses if ubiquitous growth
signalling overrides normal growth-immune trade-offs. Considering
our data, we find some support for such notions, although in other
cases the findings are counter-intuitive to the same ideas.
Table 3. Effect of polyinosinic–polycytidylic acid (Poly I:C) on expression of growth hormone (GH) and insulin-like growth factor (IGF) systemgenes
comparing wild-type with transgenic coho salmon groups
Gene
P-value
treatment
P-value treatment ×
group interaction
WT fold-change;
transcript level
TR fold-change;
transcript level
TR fold-change;
transcript level
Hormones
GH 0.48 0.63
IGF-I 0.74 0.15
IGF-II‡ <0.0001 0.001 1.20; 0.22±0.03a 0.43*; 0.18±0.05a 0.46*; 0.15±0.08a
Receptors
GHR1‡ 0.05 <0.0001 0.44; 0.64±0.38a 1.34; 1.15±0.14a 3.80*; 1.24±0.30a
GHR2‡ 0.33 0.38
IGF1R-a1 0.56 0.06
IGF1R-a2 0.17 <0.0001 2.16*; 0.68±0.13a 0.73; 0.32±0.08a,b 0.42*; 0.31±0.07b
IGF1R-b 0.03 <0.0001 1.70; 0.12±0.04a 0.34*; 0.03±0.01b 0.32*; 0.03±0.01b
IGF-binding proteins
IGFBP-1A1 0.07 0.02 1.40; 0.18±0.11a 0.61; 0.08±0.03b 0.21*; 0.04±0.02b
IGFBP-1A2‡ 0.05 <0.0001 2.52*; 0.34±0.10a 0.43*; 0.12±0.04b 0.30*; 0.15±0.04b
IGFBP-2A‡ 0.05 0.001 2.91; 0.64±0.73a 0.46*; 0.19±0.06a 0.24*; 0.20±0.13a
IGFBP-3A1 0.02 0.14
IGFBP-3A2 0.25 0.001 2.38; 0.47±0.21a 0.49; 0.21±0.07a,b 0.42; 0.18±0.12b
IGFBP-4‡ 0.70 0.61
IGFBP-5A‡ 0.14 0.29
IGFBP-5B1‡ 0.70 0.11
IGFBP-5B2 0.01 0.03 1.16; 0.87±0.22a 0.50*; 0.61±0.08a 0.54*; 0.52±0.26a
IGFBP-6B1‡ <0.0001 0.01 0.90; 0.15±0.05a 0.20*; 0.09±0.04a 0.33*; 0.09±0.06a
IGFBP-6B2 0.01 0.01 1.44; 1.24±0.33a 0.54*; 1.30±0.54a 0.42*; 0.81±0.32a
Muscle growth status markers
FBXO32‡ 0.20 0.13
TNNI2 0.20 0.03 0.60; 295.6±59.1a 1.42; 481.5±195.7a,b 2.08; 676.0±218.4b
MYL1 0.33 0.72
myoG 0.71 0.04 1.67; 0.97±0.35a 0.73; 0.70±0.06a 0.98; 0.67±0.23a
MyoD1a <0.0001 0.01 0.83; 2.34±0.57a 0.60; 2.19±0.19a 0.37*; 1.79±0.43a
Fold-change values (underlined: calculated by dividing the mean Poly I:C treatment by the mean control treatment transcript levels, N=5 fish per mean) are
given for genes where a significant treatment × group interaction was recorded by two-way ANOVA (the symbol ‘*’ indicates a significant expression change
according to Tukey’s post hoc test). For the same genes, relative transcript levels are shown post-Poly I:C treatment (means±s.d., N=5) and represent arbitrary
units normalised to two empirically validated reference genes (RpL13 and ACTB) that are quantitatively comparable across genes and among fish groups
(different superscript letters highlight significant differences among groups according to Tukey’s post hoc test). The symbol ‘‡’ shows genes where the data
required Box–Cox transformation.
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In response to both PGN and Poly I:C, the GH receptor GHR1
was upregulated in TF, with post-treatment transcript levels higher
than WT, with WT downregulating GHR1 in response to PGN.
As GH receptors are required for GH signalling, their upregulation
in the TF group suggests augmentation of GH signal and therefore
allocation into growth during immune stimulation, whereas
downregulation observed in WT to PGN should inhibit growth.
These data are consistent with the presence of a growth-immune
trade-off in the WT group following treatment with a bacterial
immune mimic, a response that is either absent (TR) or even highly
misregulated (TF) in GH transgenics.
Many IGFBP-encoding genes were differentially regulated in WT
versus GH transgenic muscle in response to immune stimulation,
indicative of distinct local regulation of IGF signalling. IGFBP genes
were systematically downregulated in GH transgenics, usually
to a greater extent in TF than TR, but were never significantly
downregulated in WT and in several cases upregulated (e.g.
IGFBP-1A genes for PGN and Poly I:C; IGFBP-6B1 for PGN).
IGFBPs play complex roles in regulating the availability of free
IGFs to IGF1R, and have diverse IGF-independent functions
(reviewed in Garcia de la serrana and Macqueen, 2018). IGFBP-1
sub-types inhibit IGF signalling by sequestering IGFs in the
extracellular environment and are major carriers of circulating IGF
(Shimizu and Dickhoff, 2017). While their autocrine roles in
teleost muscle are poorly understood, IGFBP-1A subtypes are
thought to have evolved local functions, and are upregulated by
catabolic signals in muscle (Garcia de la serrana and Macqueen,
2018). The upregulation of IGFBP-1A genes in WT fish to a level
higher than TR and TF should therefore restrict IGF signalling and
hence growth upon immune stimulation, whereas downregulation
in GH transgenic fish should increase IGF availability to IGF1R.
The observed downregulation of IGFBP-2A to immune stimulation in
GH transgenics may serve a similar purpose, as IGFBP-2 is credited
with IGF-inhibiting functions in muscle (Swiderski et al., 2016).
IGFBP-6-encoding genes were either upregulated in WT fish by
immune stimulation (i.e. IGFBP-6B1 for PGN) or downregulated in
GH transgenics (e.g. IGFBP-6B1 and -6B2 for Poly I:C in TR and
TR). IGFBP-6 subtypes are considered negative regulators of growth
(Garcia de la serrana and Macqueen, 2018) and are known to be
induced by pro-inflammatory signals in Atlantic salmon muscle
(Pooley et al., 2013). The reciprocal regulation of many IGFBPs
during immune stimulation in TR and TF versus WT fish implies
disruption in normal molecular cross-talk between growth and
immunity owing to GH and its ability to impact growth rate and
nutritional status. Past work in other salmonid species suggests that
upregulation of growth-inhibiting IGFBP genes upon immune
activation is driven by Type-I interferon signalling for antiviral
responses or TNF-α/IL-1β cytokine signalling for inflammatory
responses to bacteria (Pooley et al., 2013; Alzaid et al., 2016b).
Considering the apparent attenuation of the same immune pathways
observed in our study, we hypothesise that similar molecular
mechanisms are thought to be involved in coho salmon, and
contribute to the altered IGFBP regulation observed in GH
transgenesis.
While the above data are consistent with the growth-immune
trade-off hypothesis, the regulation of other IGF system genes was
consistent with the activation of IGF signalling in wild-type fish
in response to immune stimulation. For example, transcript levels
for IGF1R subtypes increased in WT fish in response to PGN
(IGF1R-a1) and Poly I:C (IGF1R-a2). The same genes were
significantly downregulated in the TF group, to a level below WT.
As IGF1R is required to activate the PI3K–Akt–mTOR pathway, this
implies an activation of muscle growth in WT but downregulation
in GH transgenics achieving maximal growth. In a similar fashion,
IGF-IIwas upregulated inWT in response to PGN, and downregulated
in GH transgenics in response to PGN (TR only) and Poly I:C
(TR and TF). Such findings are incompatible with the growth-
immune trade-off hypothesis but nonetheless again demonstrate
that the normal WT response of growth genes to immune stimulation
is disrupted by GH transgenesis. Such data highlight the extensive
complexity of the interaction between growth and immune function
in muscle that represents a promising direction for ongoing research
effort, which should take into account additional tissues, and perhaps
more deeply dissect molecular signatures through transcriptomic or
proteomic approaches.
Broader perspectives
This study demonstrates that GH transgenesis, and associated changes
in growth rate under different nutritional regimes (feed intake and
energy status), disrupts immune function in coho salmon muscle,
impacting normal cross-talk with growth systems. It will be important
to determine whether similar immune-related effects occur in the
muscle of domesticated fish strains, where artificial selection for fast
growth has occurred across multiple generations with opportunity for
co-adaptation and compensatory selective responses. Together with
past reports of altered immune function in GH transgenics (Jhingan
et al., 2003; Kim et al., 2013), our finding that the muscle of GH
transgenic salmon achieving maximal growth lacked any detectable
antiviral response, and showed a baseline upregulation of TNF-α
expression, has implications for the health/welfare of GH transgenic
strains destined for aquaculture, where rapid growth is the central goal
of production. Finally, our data have ramifications for environmental
risk assessments (Devlin et al., 2015) tasked with determining the
fitness and potential impacts of genetically engineered fishes should
they enter natural environments.
Acknowledgements
We thank Dwight Causey (Macqueen lab, University of Aberdeen) for providing
critical comments on the manuscript.
Competing interests
The authors declare no competing or financial interests.
Author contributions
Conceptualization: J.-H.K., R.H.D., S.A.M.M., D.J.M.; Methodology: J.-H.K., R.H.D.,
D.J.M.; Validation: A.A.; Formal analysis: A.A., D.J.M.; Investigation: A.A., J.-H.K.,
R.H.D., D.J.M.; Resources: R.H.D., S.A.M.M., D.J.M.; Data curation: A.A., D.J.M.;
Writing - original draft: A.A., D.J.M.; Writing - review & editing: J.-H.K., R.H.D.,
S.A.M.M., D.J.M.; Visualization: A.A., D.J.M.; Supervision: R.H.D., S.A.M.M.,
D.J.M.; Project administration: J.-H.K., R.H.D., S.A.M.M., D.J.M.; Funding
acquisition: R.H.D., S.A.M.M., D.J.M.
Funding
A.A. was supported by a PhD studentship from Kuwait University. The research
was supported by the Canadian Regulatory System for Biotechnology
(R.H.D., J.H.K.).
Supplementary information
Supplementary information available online at
http://jeb.biologists.org/lookup/doi/10.1242/jeb.173146.supplemental
References
Alzaid, A., Martin, S. A. and Macqueen, D. J. (2016a). The complete salmonid
IGF-IR gene repertoire and its transcriptional response to disease. Sci. Rep. 6,
34806.
Alzaid, A., Castro, R., Wang, T., Secombes, C. J., Boudinot, P., Macqueen, D. J.
and Martin, S. A. M. (2016b). Cross talk between growth and immunity: coupling
of the IGF Axis to conserved cytokine pathways in rainbow trout. Endocrinology
157, 1942-1955.
8
RESEARCH ARTICLE Journal of Experimental Biology (2018) 221, jeb173146. doi:10.1242/jeb.173146
Jo
u
rn
al
o
f
Ex
p
er
im
en
ta
lB
io
lo
g
y
Andersen, C. L., Jensen, J. L. and Ørntoft, T. F. (2004). Normalization of real-time
quantitative reverse transcription-PCR data: a model-based variance estimation
approach to identify genes suited for normalization, applied to bladder and colon
cancer data sets. Cancer Res. 64, 5245-5250.
Arendt, J. D. (1997). Adaptive intrinsic growth rates: an integration across taxa.
Q. Rev. Biol. 72, 149-177.
Bonneaud, C., Mazuc, J., Gonzalez, G., Haussy, C., Chastel, O., Faivre, B. and
Sorci, G. (2003). Assessing the cost of mounting an immune response. Am. Nat.
161, 367-379.
Bower, N. I., Li, X., Taylor, R. and Johnston, I. A. (2008). Switching to fast growth:
the insulin-like growth factor (IGF) system in skeletal muscle of Atlantic salmon.
J. Exp. Biol. 211, 3859-3870.
Breves, J. P., Phipps-Costin, S. K., Fujimoto, C. K., Einarsdottir, I. E., Regish,
A. M., Björnsson, B. T. and McCormick, S. D. (2016). Hepatic insulin-like
growth-factor binding protein (igfbp) responses to food restriction in Atlantic
salmon smolts. Gen. Comp. Endocrinol. 233, 79-87.
Castro, R., Jouneau, L., Tacchi, L., Macqueen, D. J., Alzaid, A., Secombes, C. J.,
Martin, S. A. and Boudinot, P. (2015). Disparate developmental patterns of
immune responses to bacterial and viral infections in fish. Sci. Rep. 5, 15458.
Chen, S.-E., Jin, B. and Li, Y.-P. (2007). TNF-α regulates myogenesis and muscle
regeneration by activating p38 MAPK. Am. J. Physiol. Cell Physiol.
292, C1660-C1671.
Costamagna, D., Costelli, P., Sampaolesi, M. and Penna, F. (2015). Role of
inflammation in muscle homeostasis and myogenesis. Mediators Inflamm. 2015,
805172.
Devlin, R. H., Yesaki, T. Y., Biagi, C. A., Donaldson, E. M., Swanson, P. and
Chan, W.-K. (1994). Extraordinary salmon growth. Nature 371, 209-210.
Devlin, R. H., D’Andrade, M., Uh, M. and Biagi, C. A. (2004). Population effects
of growth hormone transgenic coho salmon depend on food availability
and genotype by environment interactions. Proc. Natl. Acad. Sci. USA
101, 9303-9308.
Devlin, R. H., Sakhrani, D., Tymchuk, W. E., Rise, M. L. and Goh, B. (2009).
Domestication and growth hormone transgenesis cause similar changes in gene
expression in coho salmon (Oncorhynchus kisutch). Proc. Natl. Acad. Sci. USA
106, 3047-3052.
Devlin, R. H., Sundstrom, L. F. and Leggatt, R. A. (2015). Assessing ecological
and evolutionary consequences of growth-accelerated genetically engineered
fishes. Bioscience 7, 685-700.
Egerman, M. A. and Glass, D. J. (2014). Signaling pathways controlling skeletal
muscle mass. Crit. Rev. Biochem. Mol. Biol. 49, 59-68.
Firth, S. M. andBaxter, R. C. (2002). Cellular actions of the insulin-like growth factor
binding proteins. Endocr. Rev. 23, 824-854.
Fox, B. K., Breves, J. P., Davis, L. K., Pierce, A. L., Hirano, T. and Grau, E. G.
(2010). Tissue-specific regulation of the growth hormone/insulin-like growth factor
axis during fasting and re-feeding: importance of muscle expression of IGF-I and
IGF-II mRNA in the tilapia. Gen. Comp. Endocrinol. 166, 573-580.
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